ArticleBMC cancer2025
Skeletal muscle loss and associated clinical outcomes in patients with small-cell lung cancer receiving concurrent chemoradiotherapy.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Computed tomography-derived body composition and early changes predict outcomes of first-line chemo-immunotherapy in recurrent/metastatic nasopharyngeal carcinoma.The oncologist · 2026Article
- HyperSightRadiation oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLow muscle mass. and skeletal muscle loss have been associated with prognosis in patients with cancer. This study evaluated the effects of changes in the skeletal muscle index (SMI) on overall survival in patients with limited-stage small-cell lung cancer (LD-SCLC) undergoing concurrent chemoradiotherapy (CCRT).
methodsThis retrospective study included 55 patients with LD-SCLC who underwent CCRT. Body composition analysis was performed at baseline and post-treatment to determine changes in body mass index (BMI), the SMI at the fourth thoracic vertebral level (T4), and the SMI and areas of fat at the third lumbar vertebral level (L3). The prognostic impact of these parameters was evaluated.
resultsAt baseline, 44.6% of patients had L3 low muscle mass. according to Korean population-specific criteria. Median changes in the L3 SMI, T4 SMI, BMI, and body weight after CCRT were - 5.8 cm
conclusionSkeletal muscle loss during CCRT, particularly a decrease in L3 SMI, was associated with inferior overall survival in LD-SCLC patients. Monitoring and mitigating skeletal muscle loss may improve patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.